Allison Swartz Sells 599 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $25.08, for a total value of $15,022.92. Following the transaction, the executive vice president directly owned 82,378 shares in the company, valued at $2,066,040.24. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Wednesday, June 3rd, Allison Swartz sold 1,199 shares of Progyny stock. The stock was sold at an average price of $25.02, for a total value of $29,998.98.

Progyny Trading Up 1.5%

PGNY stock opened at $25.86 on Friday. The firm has a market capitalization of $2.03 billion, a PE ratio of 33.58, a PEG ratio of 2.28 and a beta of 1.03. Progyny, Inc. has a 1-year low of $16.10 and a 1-year high of $28.75. The business’s 50 day simple moving average is $20.58 and its 200 day simple moving average is $22.30.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue was down 26.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, sell-side analysts predict that Progyny, Inc. will post 1.07 EPS for the current fiscal year.

Progyny declared that its board has authorized a share repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Progyny

A number of hedge funds and other institutional investors have recently modified their holdings of PGNY. Royal Bank of Canada lifted its holdings in shares of Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after buying an additional 10,340 shares in the last quarter. Amundi lifted its holdings in shares of Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after buying an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after buying an additional 14,297 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Progyny by 37.4% during the second quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after buying an additional 103,253 shares in the last quarter. Finally, Walleye Capital LLC lifted its holdings in shares of Progyny by 6.9% during the second quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after buying an additional 780 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $30.00 target price on shares of Progyny in a research report on Friday, March 6th. Citizens Jmp upped their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research report on Monday, May 11th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Finally, Truist Financial lifted their target price on Progyny from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.67.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.